Neutralization of primary human immunodeficiency virus type 1 isolates: A study of parameters implicated in neutralization in vitro

AIDS Research and Human Retroviruses

Volumn 13, Issue 1, 1997, Pages 19-27

  Moog, Christiane ^a   Spenlehauer, Catherine ^a   Fleury, Hervé ^b   Heshmati, Farhad ^c   Saragosti, Sentob ^d   Letourneur, Franck ^d   Kirn, André ^a   Aubertin, Anne Marie ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Service d'Hémobiologie Transfusion   (France)

^d Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

EID: 0031030432     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.19     Document Type: Article

References (41)

1. De Jong JJ, De Ronde A, Keulen W, Termsette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 1992;66:6777-6780.
2. Shioda T, Levy JA, and Cheng-Mayer C: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992;89:9434-9438.
3. Daar ES, Ling X, Moudgil T, and Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990;87:6574-6578.
4. Conley AJ, Gorny MK, Kessler JA, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, and Zolla-Pazner S: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
5. Cohen J: Jitters jeopardize AIDS vaccine trials. Science 1993;262:980-981.
6. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, and Norcross MA: Cryptic nature of the envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
7. Sawyer LSW, Wrin MT, Crawford-Miksza L, Potts B, Wu Y, Weber PA, Alfonso RD, and Hanson CV: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994;68:1342-1349.
8. Matthews T: Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994;10:631-632.
9. Golding H, D'Souza P, Bradac J, Mathieson B, and Fast P: Neutralization of HIV-1. AIDS Res Hum Retroviruses 1994;10: 633-643.
10. D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, Milman G, and Collaborating Investigators: Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: An international collaboration. AIDS 1994;8:169-181.
11. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, Hendry RM, and Collaborating Investigators: Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 1995;9:867-874.
12. Mascola JR, Louder M, Surman S, Bradac J, Porter KR, Carr J, Mason C, McNeil JG, Birx DL, McCutchan FE, and Burke DS: An approach of human immunodeficiency virus type 1 neutralizing antibody serotyping. In: 10th Colloque des Cent Gardes. Elsevier, Paris, 1995, pp. 65-71.
13. Baldinotti F, Matteucci D, Mazzetti P, Giannelli C, Bandecchi P, Tozzini F, and Bendinelli M: Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol 1994;68:4572-4579.
14. Wrin T, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH: Adaptation to persistent growth in H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
15. Gallo D, Kimpton JS, and Daily PJ: Comparative studies on use of fresh and frozen peripheral blood lymphocytes specimens for isolation of human immunodeficiency syndrome virus and effects of cell lysis on isolation efficiency. J Clin Microbiol 1987;25:1291-1294.
16. Moog C, Wick A, Le Ber P, Kirn A, and Aubertin AM: Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Res 1994;12:275-288.
17. Girard M, Kieny MP, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman J, and Fultz P: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-546.
18. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
19. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, and Oshiro LS: Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984;225:840-842.
20. Working Group on Neutralizing Antibodies (ANRS, France): A consensus assay using PBL cultures for quantitative on neutralizing antibodies to HIV-1. In: IXth International Conference on AIDS, Berlin, June 1993. [Abstract BA210465].
21. Burns DPW and Desrosiers RC: A caution on the use of SIV/HIV Gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses 1992;8:1189-1192.
22. Albert J, Björling E, Gegerfelt A, Scarlatti G, Zhang Y-J, Fenyö EM, and Thorstensson R: Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Res Hum Retroviruses 1993;9:501-504.
23. Mascola JR and Bruke DS: Antigen detection in neutralization assays: High levels of interfering anti-p24 antibodies in some plasma. AIDS Res Hum Retroviruses 1993;9:1173-1174.
24. Reed LJ and Muench H: A simple method of estimating fifty percent end points. Am J Hyg 1938;27:493-497.
25. Chaix ML, Chappey C, Couillin I, Rozenbaum W, Levy JP, and Sarogosti S: Diversity of V3 region of HIV in Paris, France. AIDS 1993;7:1199-1204.
26. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Grose GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, and Burke DS: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
27. VanCott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, and Birx DL: Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
28. Sanchez-Pescador R, Power MD, Barr PJ, Steimer KS, Stempien MM, Brown-Shimer SL, Gee WW, Renard A, Randolph A, Levy JA, Dina D, and Luciw PA: Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 1985;227:484-492.
29. Moore JP, Burkly LC, Connor RI, Cao Y, Tizard R, Ho DD, and Fisher RA: Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the response of their envelope glycoproteins to soluble CD4. AIDS Res Hum Retroviruses 1993;9:529-539.
30. Spira AI and Ho DD: Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J Virol 1995;69:422-429.
31. Williams LM and Cloyd MW: Polymorphic human gene(s) determines differential susceptibility of CD-4 lymphocytes to infection by certain HIV-1 isolates. Virology 1991;184:723-728.
32. Boyd MT, Simpson GR, Cann AJ, Johnson MA, and Weiss AA: A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp 120 alters cellular tropism. J Virol 1993;67:3549-3652.
33. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science 1992;257:535-357.
34. Orloff SL, Bandea CI, Kennedy MS, Allaway GP, Maddon PJ, and McDouglas JS: Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: Association with sequence differences in the first constant (C1) region of glycoprotein 120. AIDS Res Hum Retroviruses 1995;11:335-342.
35. Stamatatos L, Werner A, and Cheng-Mayer C: Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J Virol 1994;68:4973-4979.
36. Koito A, Harrowe G, Levy JA, and Cheng-Mayer C: Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994; 68:2253-2259.
37. O'Brien WA, Mao S-H, Cao Y, and Moor JP: Macrophage-tropic and T-cell line adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J Virol 1994;68:5264-5269.
38. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton D, and Ho DD: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
39. Moore JP, Cao Y, Ho DD, and Koup R: Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994;68:5142-5155.
40. Tsang ML, Evans LA, McQueen P, Hurren L, Byrne C, Penny R, Tindall B, and Cooper DA: Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994;170:1141-1147.
41. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, and Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312-8320.